MedTrace Logo

VELCADE,Rituximab,Cyclophosphamide and Decadron

NCT00413959 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell

Interventions

DRUG

VELCADE®

1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.

DRUG

Rituximab

375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.

DRUG

Cyclophosphamide

400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.

DRUG

Decadron

40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Oncology Specialists, S.C.

    lead OTHER

Principal Investigators

  • Chadi Nabhan, MD · Oncology Specialists, SC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413959 on ClinicalTrials.gov